Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: A seal failure prediction system consisting of a seal component and a member conveniently placed; such member, which may be in the form of a strip, a set of wires, or a single wire, generating a characteristic electrical or audible signal when the seal component wears a certain amount.

Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Abstract: Aspects of the present disclosure include a connector, an array of connectors, a method for manufacturing the connectors, and a method for using the connectors. The connectors are capable of carrying electrical or electric signal and include geometries to operate in holding, latching, or locking applications. The connector can include a contact housing formed by a first electrically conductive housing, a second electrically conductive housing and a housing sealing component at least partially isolating said first and second electrically conductive housings from each other. A body, such as a pin, a rod, or an elongated member, is provided. A first electrically conductive spring is located in a first groove and a second electrically conductive spring is located in a second groove inside the contact housing. Wherein a first electrical path and a second electrical path are formed when the body is inserted into the contact housing. In other examples, more than two electrical paths can be provided.

Abstract: Electrical resistance between a male part and a female part through a canted spring is disclosed using mathematical modeling. Increase or decrease in resistance can be quickly analyzed by looking at the equivalence resistance and the number of contacts at the input side, the output side, or both. The number of contacts may also be created by forming a dimple having a discontinuity.

Abstract: A contact assembly is disclosed herein with a spring contact located in a housing wherein a plurality of coils of the spring contact are interconnected with one another and all slanted or canted. The coils further have outside diameters of different outside dimensions, such as one section of the spring contact having a larger outside diameter than the other section or sections of the spring contact. When inside the interior cavity of the housing, the first end and the second end are spaced from one another and wherein some of the plurality of coils do not contact the housing. A pin, rod, or shaft is locatable in a passage of the spring contact of the contact assembly but less than all of the coils of the spring contact grip against the exterior surface of the pin, rod or shaft.

Abstract: Aspects of the present disclosure include a connector, an array of connectors, a method for manufacturing the connectors, and a method for using the connectors. The connectors are capable of carrying electrical or electric signal and include geometries to operate in holding, latching, or locking applications. The connector can include a contact housing formed by a first electrically conductive housing, a second electrically conductive housing and a housing sealing component at least partially isolating said first and second electrically conductive housings from each other. A body, such as a pin, a rod, or an elongated member, is provided. A first electrically conductive spring is located in a first groove and a second electrically conductive spring is located in a second groove inside the contact housing. Wherein a first electrical path and a second electrical path are formed when the body is inserted into the contact housing. In other examples, more than two electrical paths can be provided.

Abstract: Cosmic spike filters are provided, which remove noise spikes in spectral data. Spikes are eliminated by locating, smoothing and filtering the spikes using replicates to improve the accuracy of the spike detection process compared to when only one replicate is used. Cosmic spike filters are also provided that combine a data collection approach and a statistical approach to remove cosmic spike noise from the collected signal without distorting the true signal. Still further, a statistical approach is provided to identify and remove negative peaks from a spectrum, where the negative peaks are caused by bad pixels in a charge coupled device.

Abstract: A contact assembly is disclosed herein with a spring contact located in a housing wherein a plurality of coils of the spring contact are interconnected with one another and all slanted or canted. The coils further have outside diameters of different outside dimensions, such as one section of the spring contact having a larger outside diameter than the other section or sections of the spring contact. When inside the interior cavity of the housing, the first end and the second end are spaced from one another and wherein some of the plurality of coils do not contact the housing. A pin, rod, or shaft is locatable in a passage of the spring contact of the contact assembly but less than all of the coils of the spring contact grip against the exterior surface of the pin, rod or shaft.

Abstract: A seal failure prediction system consisting of a seal component and a member conveniently placed; such member, which may be in the form of a strip, a set of wires, or a single wire, generating a characteristic electrical or audible signal when the seal component wears a certain amount.

Abstract: Electrical resistance between a male part and a female part through a canted spring is disclosed using mathematical modeling. Increase or decrease in resistance can be quickly analyzed by looking at the equivalence resistance and the number of contacts at the input side, the output side, or both. The number of contacts may also be created by forming a dimple having a discontinuity.